SC 13G/A | 2018-02-09 | DIMENSIONAL FUND ADVISORS LP | SCICLONE PHARMACEUTICALS INC | 0 | 0.0% | EDGAR |
SC 13D/A | 2017-10-17 | Man Group plc | SCICLONE PHARMACEUTICALS INC | - | 0.0% | EDGAR |
SC 13D/A | 2017-10-16 | GL Partners Capital Management Ltd | SCICLONE PHARMACEUTICALS INC | 0 | 0.0% | EDGAR |
SC 13D | 2017-07-27 | Man Group plc | SCICLONE PHARMACEUTICALS INC | 2,837,565 | 5.5% | EDGAR |
SC 13D/A | 2017-06-08 | GL Partners Capital Management Ltd | SCICLONE PHARMACEUTICALS INC | 4,750,116 | 9.2% | EDGAR |
SC 13D/A | 2017-02-21 | Jade Park Investments Ltd | SCICLONE PHARMACEUTICALS INC | 8,888 | 0.0% | EDGAR |
SC 13D/A | 2017-02-17 | GL Partners Capital Management Ltd | SCICLONE PHARMACEUTICALS INC | 4,750,116 | 9.3% | EDGAR |
SC 13D/A | 2017-02-17 | Ally Bridge LB Healthcare Master Fund Ltd | SCICLONE PHARMACEUTICALS INC | 678,077 | 1.3% | EDGAR |
SC 13G | 2017-02-13 | VANGUARD GROUP INC | SCICLONE PHARMACEUTICALS INC | 2,700,061 | 5.3% | EDGAR |
SC 13G/A | 2017-02-09 | Man Group plc | SCICLONE PHARMACEUTICALS INC | 932,697 | 1.8% | EDGAR |
SC 13G | 2017-02-09 | DIMENSIONAL FUND ADVISORS LP | SCICLONE PHARMACEUTICALS INC | 2,888,743 | 5.7% | EDGAR |
SC 13G/A | 2017-01-17 | BlackRock Inc. | SCICLONE PHARMACEUTICALS INC | 6,912,779 | 13.5% | EDGAR |
SC 13D/A | 2016-11-15 | Jade Park Investments Ltd | SCICLONE PHARMACEUTICALS INC | 8,888 | 0.0% | EDGAR |
SC 13D/A | 2016-11-14 | GL Partners Capital Management Ltd | SCICLONE PHARMACEUTICALS INC | 4,750,116 | 9.3% | EDGAR |
SC 13D/A | 2016-11-14 | Ally Bridge LB Healthcare Master Fund Ltd | SCICLONE PHARMACEUTICALS INC | 678,077 | 1.3% | EDGAR |
SC 13G | 2016-09-22 | Man Group plc | SCICLONE PHARMACEUTICALS INC | 2,562,923 | 5.1% | EDGAR |
SC 13G | 2016-09-19 | SCICLONE PHARMACEUTICALS INC | SOLIGENIX, INC. | 3,529,412 | 9.4% | EDGAR |
SC 13G/A | 2016-09-09 | FRANKLIN RESOURCES INC | SCICLONE PHARMACEUTICALS INC | 2,429,532 | 4.9% | EDGAR |
SC 13G/A | 2016-05-09 | FRANKLIN RESOURCES INC | SCICLONE PHARMACEUTICALS INC | 5,071,331 | 10.2% | EDGAR |
SC 13D/A | 2016-02-22 | GL Partners Capital Management Ltd | SCICLONE PHARMACEUTICALS INC | 4,750,116 | 9.6% | EDGAR |